Kojanova, Martina
Turkova, Barbora
Gkalpakiotis, Spyridon
Cetkovska, Petra
Fialova, Jorga
Dolezal, Tomas
Machovcova, Alena
Apol, Eydna Didriksen
,
Funding for this research was provided by:
Charles University
Article History
Received: 22 May 2024
Accepted: 19 July 2024
First Online: 29 August 2024
Declarations
:
: Martina Kojanova, Spyridon Gkalpakiotis, Petra Cetkovska, Jorga Fialova, Alena Machovcova, and Tomas Dolezal have served as consultants, speakers, or investigators for AbbVie, Amgen, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, and UCB. Barbora Turkova declares that she has nothing to disclose. Eydna Didriksen Apol is an employee of Leo Pharma A/S.
: The study was conducted in accordance with good pharmacoepidemiology practices by research groups belonging to the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), in accordance with the ENCePP Code of Conduct and, if possible, under the ENCePP Study Seal. Patient-level data used for this analysis were de-identified, and Institutional Review Board approval was not required for this study. Permission to access/use data from BIOREP registry was obtained.